| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 53 | 2024 | 284 | 9.340 |
Why?
|
| Influenza, Human | 49 | 2024 | 277 | 8.700 |
Why?
|
| Vaccination | 76 | 2024 | 664 | 7.970 |
Why?
|
| Pregnancy Complications, Infectious | 22 | 2024 | 139 | 5.060 |
Why?
|
| Papillomavirus Vaccines | 17 | 2023 | 119 | 4.350 |
Why?
|
| Papillomavirus Infections | 15 | 2023 | 131 | 3.750 |
Why?
|
| Humans | 195 | 2024 | 18058 | 3.210 |
Why?
|
| Pregnancy | 54 | 2024 | 1484 | 3.040 |
Why?
|
| Adult | 122 | 2024 | 7696 | 3.030 |
Why?
|
| Adolescent | 91 | 2024 | 3714 | 3.020 |
Why?
|
| Female | 147 | 2024 | 12838 | 2.800 |
Why?
|
| Young Adult | 81 | 2024 | 2479 | 2.740 |
Why?
|
| Child | 60 | 2024 | 2519 | 2.520 |
Why?
|
| Hospitalization | 26 | 2024 | 813 | 2.450 |
Why?
|
| Rotavirus Vaccines | 6 | 2024 | 50 | 2.390 |
Why?
|
| Vaccines | 16 | 2021 | 222 | 2.190 |
Why?
|
| United States | 73 | 2024 | 4119 | 2.110 |
Why?
|
| Uterine Cervical Neoplasms | 8 | 2022 | 123 | 1.900 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 15 | 2023 | 95 | 1.850 |
Why?
|
| Retrospective Studies | 43 | 2024 | 2498 | 1.760 |
Why?
|
| Infant | 48 | 2023 | 1212 | 1.740 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 15 | 2019 | 105 | 1.720 |
Why?
|
| Male | 87 | 2024 | 10173 | 1.650 |
Why?
|
| Health Personnel | 11 | 2022 | 122 | 1.540 |
Why?
|
| Viral Vaccines | 3 | 2023 | 15 | 1.530 |
Why?
|
| Gastroenteritis | 4 | 2024 | 25 | 1.500 |
Why?
|
| Middle Aged | 59 | 2024 | 8073 | 1.380 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 12 | 2024 | 56 | 1.380 |
Why?
|
| Emergency Service, Hospital | 12 | 2024 | 357 | 1.380 |
Why?
|
| Child, Preschool | 36 | 2024 | 1428 | 1.340 |
Why?
|
| Delivery of Health Care, Integrated | 9 | 2024 | 552 | 1.230 |
Why?
|
| Condylomata Acuminata | 2 | 2020 | 23 | 1.210 |
Why?
|
| Rotavirus | 3 | 2022 | 18 | 1.200 |
Why?
|
| Rotavirus Infections | 3 | 2022 | 31 | 1.200 |
Why?
|
| Infant, Newborn | 31 | 2024 | 852 | 1.180 |
Why?
|
| Cohort Studies | 40 | 2023 | 2631 | 1.130 |
Why?
|
| Prospective Studies | 29 | 2024 | 1294 | 1.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2022 | 118 | 1.100 |
Why?
|
| Vaccines, Inactivated | 16 | 2024 | 70 | 1.100 |
Why?
|
| Hepatitis B Vaccines | 3 | 2018 | 46 | 1.060 |
Why?
|
| Oregon | 12 | 2024 | 195 | 1.040 |
Why?
|
| Incidence | 20 | 2021 | 1297 | 1.010 |
Why?
|
| Norovirus | 1 | 2024 | 4 | 0.960 |
Why?
|
| Immunization, Secondary | 8 | 2022 | 64 | 0.950 |
Why?
|
| Premature Birth | 10 | 2024 | 135 | 0.950 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2023 | 3 | 0.910 |
Why?
|
| Pregnancy Outcome | 9 | 2024 | 158 | 0.870 |
Why?
|
| Whooping Cough | 7 | 2023 | 75 | 0.820 |
Why?
|
| Case-Control Studies | 17 | 2023 | 1164 | 0.810 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 3 | 2017 | 33 | 0.800 |
Why?
|
| Hepatitis A Vaccines | 2 | 2019 | 14 | 0.790 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 19 | 0.790 |
Why?
|
| Vaccines, Combined | 13 | 2024 | 90 | 0.770 |
Why?
|
| Smallpox Vaccine | 4 | 2023 | 6 | 0.740 |
Why?
|
| Pregnancy Complications | 5 | 2017 | 193 | 0.740 |
Why?
|
| Seizures, Febrile | 7 | 2017 | 47 | 0.730 |
Why?
|
| Aged | 33 | 2024 | 6258 | 0.730 |
Why?
|
| Prenatal Care | 6 | 2017 | 136 | 0.720 |
Why?
|
| RNA, Messenger | 10 | 2024 | 79 | 0.710 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2019 | 5 | 0.710 |
Why?
|
| Hepatitis A | 1 | 2019 | 10 | 0.710 |
Why?
|
| Databases, Factual | 10 | 2016 | 330 | 0.700 |
Why?
|
| Papillomaviridae | 4 | 2020 | 47 | 0.700 |
Why?
|
| Chickenpox Vaccine | 9 | 2020 | 101 | 0.690 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 50 | 0.650 |
Why?
|
| Pregnant Women | 4 | 2021 | 44 | 0.650 |
Why?
|
| Abortion, Spontaneous | 5 | 2021 | 51 | 0.650 |
Why?
|
| Syncope | 1 | 2018 | 12 | 0.640 |
Why?
|
| Acute Pain | 1 | 2018 | 11 | 0.640 |
Why?
|
| Seasons | 9 | 2024 | 99 | 0.640 |
Why?
|
| Herpes Zoster | 4 | 2023 | 86 | 0.630 |
Why?
|
| Chorioamnionitis | 4 | 2023 | 18 | 0.620 |
Why?
|
| Feedback | 1 | 2017 | 23 | 0.610 |
Why?
|
| Sexual Partners | 1 | 2017 | 37 | 0.610 |
Why?
|
| Asthma | 4 | 2017 | 302 | 0.600 |
Why?
|
| Population Surveillance | 9 | 2019 | 270 | 0.590 |
Why?
|
| Product Surveillance, Postmarketing | 8 | 2016 | 113 | 0.590 |
Why?
|
| Risk Assessment | 13 | 2020 | 1137 | 0.580 |
Why?
|
| Time Factors | 13 | 2022 | 1114 | 0.580 |
Why?
|
| Fever | 5 | 2020 | 60 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 10 | 2022 | 397 | 0.530 |
Why?
|
| Immunization Schedule | 9 | 2021 | 132 | 0.520 |
Why?
|
| Vaccines, Synthetic | 7 | 2023 | 42 | 0.520 |
Why?
|
| Pregnancy Rate | 1 | 2015 | 5 | 0.520 |
Why?
|
| Rural Population | 4 | 2005 | 48 | 0.510 |
Why?
|
| Vaccines, Attenuated | 7 | 2023 | 47 | 0.510 |
Why?
|
| Photosensitivity Disorders | 2 | 2006 | 3 | 0.500 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 48 | 0.500 |
Why?
|
| Antibodies, Viral | 7 | 2024 | 64 | 0.490 |
Why?
|
| Mass Vaccination | 4 | 2019 | 22 | 0.480 |
Why?
|
| Dermatitis, Atopic | 3 | 2005 | 13 | 0.480 |
Why?
|
| Bacterial Vaccines | 1 | 2014 | 17 | 0.480 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 5 | 2020 | 67 | 0.470 |
Why?
|
| Pandemics | 5 | 2023 | 293 | 0.470 |
Why?
|
| Seizures | 4 | 2014 | 30 | 0.450 |
Why?
|
| Viral Load | 3 | 2022 | 132 | 0.440 |
Why?
|
| Vaccination Coverage | 3 | 2022 | 44 | 0.430 |
Why?
|
| Critical Illness | 2 | 2023 | 53 | 0.430 |
Why?
|
| Risk Factors | 17 | 2023 | 3394 | 0.410 |
Why?
|
| Risk | 13 | 2017 | 552 | 0.410 |
Why?
|
| Ambulatory Care | 6 | 2024 | 274 | 0.390 |
Why?
|
| Surveys and Questionnaires | 8 | 2020 | 1346 | 0.390 |
Why?
|
| Database Management Systems | 3 | 2020 | 15 | 0.390 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2016 | 30 | 0.380 |
Why?
|
| Age Factors | 10 | 2017 | 945 | 0.380 |
Why?
|
| Pericarditis | 2 | 2022 | 14 | 0.370 |
Why?
|
| Myocarditis | 2 | 2022 | 18 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2020 | 393 | 0.360 |
Why?
|
| Aged, 80 and over | 15 | 2022 | 1956 | 0.360 |
Why?
|
| Congenital Abnormalities | 4 | 2017 | 26 | 0.360 |
Why?
|
| Anemia, Hemolytic | 1 | 2009 | 2 | 0.360 |
Why?
|
| Infant, Small for Gestational Age | 4 | 2024 | 56 | 0.350 |
Why?
|
| Respiratory Tract Infections | 3 | 2014 | 53 | 0.340 |
Why?
|
| Epidemiological Monitoring | 2 | 2019 | 26 | 0.340 |
Why?
|
| Washington | 4 | 2021 | 384 | 0.340 |
Why?
|
| Tetanus | 2 | 2023 | 18 | 0.330 |
Why?
|
| Patient Compliance | 2 | 2012 | 303 | 0.330 |
Why?
|
| Prevalence | 10 | 2019 | 892 | 0.330 |
Why?
|
| Herpes Zoster Vaccine | 2 | 2023 | 62 | 0.330 |
Why?
|
| Electronic Health Records | 6 | 2023 | 734 | 0.330 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2005 | 7 | 0.320 |
Why?
|
| Agriculture | 2 | 2005 | 7 | 0.300 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 5 | 2014 | 33 | 0.300 |
Why?
|
| Eczema | 2 | 2006 | 7 | 0.300 |
Why?
|
| Intussusception | 2 | 2014 | 16 | 0.300 |
Why?
|
| Specimen Handling | 3 | 2022 | 22 | 0.300 |
Why?
|
| Alphapapillomavirus | 2 | 2020 | 14 | 0.290 |
Why?
|
| Smallpox | 2 | 2005 | 4 | 0.290 |
Why?
|
| Measles | 2 | 2020 | 26 | 0.290 |
Why?
|
| Sick Role | 1 | 2006 | 8 | 0.290 |
Why?
|
| Stillbirth | 3 | 2021 | 30 | 0.280 |
Why?
|
| Managed Care Programs | 5 | 2013 | 356 | 0.270 |
Why?
|
| European Continental Ancestry Group | 3 | 2019 | 559 | 0.260 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 595 | 0.260 |
Why?
|
| Antiviral Agents | 3 | 2022 | 96 | 0.250 |
Why?
|
| Emergency Responders | 2 | 2021 | 4 | 0.250 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 5 | 2024 | 13 | 0.250 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2004 | 4 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1309 | 0.240 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2014 | 41 | 0.240 |
Why?
|
| Immunization Programs | 4 | 2013 | 68 | 0.230 |
Why?
|
| Upper Extremity | 1 | 2023 | 6 | 0.230 |
Why?
|
| Mental Recall | 1 | 2003 | 32 | 0.230 |
Why?
|
| Antibody Formation | 3 | 2024 | 7 | 0.230 |
Why?
|
| Peripartum Period | 1 | 2023 | 2 | 0.220 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 20 | 0.220 |
Why?
|
| Internet | 2 | 2023 | 247 | 0.220 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 4 | 0.220 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2022 | 3 | 0.220 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 45 | 0.220 |
Why?
|
| Travel | 1 | 2022 | 9 | 0.220 |
Why?
|
| Quality of Life | 1 | 2006 | 509 | 0.220 |
Why?
|
| Hemagglutination Inhibition Tests | 5 | 2024 | 7 | 0.220 |
Why?
|
| Lyme Disease | 1 | 2002 | 4 | 0.210 |
Why?
|
| Social Class | 2 | 2013 | 125 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2024 | 290 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 20 | 0.200 |
Why?
|
| Occupations | 1 | 2021 | 15 | 0.200 |
Why?
|
| Feasibility Studies | 2 | 2018 | 116 | 0.200 |
Why?
|
| Occupational Diseases | 1 | 2021 | 37 | 0.190 |
Why?
|
| Insurance, Health | 2 | 2021 | 221 | 0.190 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 227 | 0.190 |
Why?
|
| Wisconsin | 4 | 2005 | 9 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 2 | 2013 | 80 | 0.190 |
Why?
|
| Logistic Models | 7 | 2020 | 953 | 0.180 |
Why?
|
| Influenza A virus | 3 | 2016 | 14 | 0.180 |
Why?
|
| Interviews as Topic | 3 | 2017 | 327 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 27 | 0.180 |
Why?
|
| Mumps | 1 | 2020 | 12 | 0.180 |
Why?
|
| Northwestern United States | 1 | 2020 | 47 | 0.180 |
Why?
|
| Herpesvirus 3, Human | 2 | 2023 | 47 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2018 | 235 | 0.180 |
Why?
|
| Preconception Care | 2 | 2017 | 45 | 0.180 |
Why?
|
| Chickenpox | 1 | 2020 | 38 | 0.180 |
Why?
|
| Contraindications | 2 | 2014 | 16 | 0.180 |
Why?
|
| Diphtheria-Tetanus Vaccine | 2 | 2009 | 3 | 0.180 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Child Development | 1 | 2020 | 49 | 0.170 |
Why?
|
| Immunity, Herd | 1 | 2019 | 5 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| Tetanus Toxoid | 2 | 2015 | 11 | 0.170 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.160 |
Why?
|
| Cryotherapy | 1 | 2018 | 4 | 0.160 |
Why?
|
| Immunization | 2 | 2021 | 79 | 0.160 |
Why?
|
| Parents | 2 | 2018 | 308 | 0.160 |
Why?
|
| Infant Mortality | 1 | 2018 | 22 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2018 | 43 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1255 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2015 | 319 | 0.160 |
Why?
|
| Patient Selection | 1 | 2019 | 194 | 0.150 |
Why?
|
| Health Status | 2 | 2013 | 331 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2014 | 19 | 0.150 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 7 | 0.150 |
Why?
|
| Gestational Age | 3 | 2013 | 119 | 0.150 |
Why?
|
| Pneumonia | 1 | 2017 | 54 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 13 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2021 | 1259 | 0.150 |
Why?
|
| Measles Vaccine | 1 | 2017 | 21 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 34 | 0.150 |
Why?
|
| Health Communication | 1 | 2017 | 17 | 0.140 |
Why?
|
| Off-Label Use | 2 | 2013 | 14 | 0.140 |
Why?
|
| Health Status Disparities | 2 | 2021 | 154 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2017 | 103 | 0.140 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2016 | 5 | 0.140 |
Why?
|
| Myelitis, Transverse | 1 | 2016 | 5 | 0.140 |
Why?
|
| Physician's Role | 1 | 2017 | 33 | 0.140 |
Why?
|
| Cause of Death | 2 | 2018 | 181 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 97 | 0.140 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2009 | 92 | 0.140 |
Why?
|
| Drug Utilization | 2 | 2013 | 134 | 0.140 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 3 | 0.140 |
Why?
|
| Health Maintenance Organizations | 3 | 2013 | 481 | 0.140 |
Why?
|
| Communication | 1 | 2017 | 205 | 0.140 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 75 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 15 | 0.130 |
Why?
|
| Mortality | 2 | 2013 | 121 | 0.130 |
Why?
|
| Aluminum | 1 | 2015 | 14 | 0.130 |
Why?
|
| Data Collection | 2 | 2013 | 276 | 0.130 |
Why?
|
| Algorithms | 2 | 2017 | 235 | 0.130 |
Why?
|
| Turbinates | 1 | 2015 | 2 | 0.130 |
Why?
|
| Nose | 1 | 2015 | 3 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 20 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 144 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2017 | 134 | 0.130 |
Why?
|
| Health Behavior | 2 | 2014 | 379 | 0.130 |
Why?
|
| Age Distribution | 3 | 2017 | 257 | 0.130 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 454 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2015 | 108 | 0.130 |
Why?
|
| Hypersensitivity | 2 | 2013 | 19 | 0.130 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 14 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2014 | 43 | 0.120 |
Why?
|
| Eclampsia | 1 | 2014 | 12 | 0.120 |
Why?
|
| Demography | 3 | 2022 | 106 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 318 | 0.120 |
Why?
|
| California | 6 | 2019 | 2327 | 0.120 |
Why?
|
| Yellow fever virus | 1 | 2013 | 1 | 0.120 |
Why?
|
| Yellow Fever Vaccine | 1 | 2013 | 1 | 0.120 |
Why?
|
| Yellow Fever | 1 | 2013 | 2 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 8 | 0.120 |
Why?
|
| Cell Culture Techniques | 2 | 2024 | 4 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 38 | 0.120 |
Why?
|
| Obstetric Labor Complications | 1 | 2013 | 14 | 0.120 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2013 | 97 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 17 | 0.110 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2013 | 16 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2013 | 4 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2014 | 164 | 0.110 |
Why?
|
| Oseltamivir | 1 | 2012 | 3 | 0.110 |
Why?
|
| Diphtheria | 1 | 2012 | 14 | 0.110 |
Why?
|
| RNA, Viral | 2 | 2022 | 62 | 0.110 |
Why?
|
| HIV Infections | 1 | 2019 | 682 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2023 | 150 | 0.100 |
Why?
|
| Denmark | 1 | 2012 | 19 | 0.100 |
Why?
|
| Medical Records | 3 | 2008 | 108 | 0.100 |
Why?
|
| Stroke | 2 | 2019 | 306 | 0.100 |
Why?
|
| Health Services | 1 | 2013 | 111 | 0.100 |
Why?
|
| Comorbidity | 3 | 2017 | 618 | 0.100 |
Why?
|
| Laboratories | 2 | 2021 | 23 | 0.100 |
Why?
|
| Focus Groups | 1 | 2012 | 152 | 0.100 |
Why?
|
| Sex Factors | 3 | 2013 | 634 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 177 | 0.100 |
Why?
|
| Skin | 1 | 2011 | 14 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 157 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2012 | 160 | 0.100 |
Why?
|
| School Health Services | 1 | 2011 | 41 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2012 | 267 | 0.090 |
Why?
|
| Safety | 2 | 2011 | 45 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 338 | 0.090 |
Why?
|
| Diphtheria Toxoid | 1 | 2009 | 4 | 0.090 |
Why?
|
| International Classification of Diseases | 3 | 2017 | 87 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2009 | 37 | 0.080 |
Why?
|
| Registries | 1 | 2011 | 486 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2009 | 46 | 0.080 |
Why?
|
| Pneumococcal Infections | 1 | 2009 | 54 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 2008 | 6 | 0.080 |
Why?
|
| Natural Language Processing | 2 | 2009 | 53 | 0.080 |
Why?
|
| Genotype | 2 | 2019 | 251 | 0.070 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2006 | 7 | 0.070 |
Why?
|
| Histamine H1 Antagonists | 1 | 2006 | 3 | 0.070 |
Why?
|
| Edema | 1 | 2006 | 5 | 0.070 |
Why?
|
| Electronics, Medical | 1 | 2006 | 3 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2019 | 692 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 255 | 0.070 |
Why?
|
| Canada | 1 | 2006 | 66 | 0.070 |
Why?
|
| Propensity Score | 2 | 2017 | 90 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 60 | 0.070 |
Why?
|
| Colorado | 1 | 2006 | 207 | 0.070 |
Why?
|
| Health Surveys | 1 | 2006 | 266 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 53 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 2 | 2017 | 39 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2005 | 9 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 2 | 2021 | 77 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 73 | 0.060 |
Why?
|
| Bias | 2 | 2016 | 109 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2017 | 192 | 0.060 |
Why?
|
| Epitopes | 1 | 2024 | 4 | 0.060 |
Why?
|
| Anaphylaxis | 2 | 2014 | 15 | 0.060 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2003 | 1 | 0.060 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 6 | 0.060 |
Why?
|
| Toxoids | 1 | 2023 | 3 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 667 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 316 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2019 | 431 | 0.060 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 3 | 0.060 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 4 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 7 | 0.050 |
Why?
|
| Texas | 2 | 2013 | 33 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 111 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2022 | 3 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 510 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2014 | 92 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 13 | 0.050 |
Why?
|
| Human papillomavirus 18 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 6 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 2013 | 10 | 0.050 |
Why?
|
| Telephone | 1 | 2003 | 175 | 0.050 |
Why?
|
| Thigh | 2 | 2013 | 11 | 0.050 |
Why?
|
| Arm | 2 | 2013 | 5 | 0.050 |
Why?
|
| Alberta | 1 | 2021 | 3 | 0.050 |
Why?
|
| Information Systems | 1 | 2021 | 22 | 0.050 |
Why?
|
| Carrier State | 1 | 2021 | 7 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 8 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 394 | 0.050 |
Why?
|
| Vaccines, Conjugate | 2 | 2013 | 66 | 0.050 |
Why?
|
| Health Facilities | 1 | 2020 | 18 | 0.050 |
Why?
|
| Israel | 1 | 2020 | 2 | 0.050 |
Why?
|
| Australia | 1 | 2020 | 20 | 0.050 |
Why?
|
| Global Health | 1 | 2020 | 29 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 10 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 16 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 25 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2002 | 251 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2019 | 2 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 317 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 35 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 53 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 49 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 445 | 0.040 |
Why?
|
| Feces | 1 | 2018 | 84 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 504 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 20 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2017 | 11 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 43 | 0.040 |
Why?
|
| Live Birth | 1 | 2017 | 8 | 0.040 |
Why?
|
| Outpatients | 1 | 2018 | 113 | 0.040 |
Why?
|
| Behavior | 1 | 2017 | 18 | 0.040 |
Why?
|
| Social Marketing | 1 | 2017 | 13 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 35 | 0.040 |
Why?
|
| Family Health | 1 | 2017 | 47 | 0.040 |
Why?
|
| Trust | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2017 | 29 | 0.040 |
Why?
|
| Educational Status | 1 | 2017 | 205 | 0.040 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
| Maternal Age | 1 | 2016 | 79 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 49 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 240 | 0.030 |
Why?
|
| Ribonuclease P | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2015 | 8 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 6 | 0.030 |
Why?
|
| Vasculitis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chills | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cough | 1 | 2014 | 17 | 0.030 |
Why?
|
| Myalgia | 1 | 2014 | 10 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2014 | 91 | 0.030 |
Why?
|
| Encephalitis | 1 | 2014 | 6 | 0.030 |
Why?
|
| Absenteeism | 1 | 2014 | 27 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2013 | 1 | 0.030 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 103 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2013 | 1 | 0.030 |
Why?
|
| Oropharynx | 1 | 2013 | 1 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2013 | 2 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 92 | 0.030 |
Why?
|
| Observation | 1 | 2013 | 25 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 86 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2013 | 22 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 17 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 34 | 0.030 |
Why?
|
| Fetal Mortality | 1 | 2013 | 2 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 2013 | 46 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 48 | 0.030 |
Why?
|
| Fetal Death | 1 | 2013 | 9 | 0.030 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 12 | 0.030 |
Why?
|
| Quality Control | 1 | 2012 | 45 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2013 | 36 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 138 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 49 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 77 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 705 | 0.030 |
Why?
|
| Smoking | 1 | 2014 | 465 | 0.030 |
Why?
|
| Self Report | 1 | 2013 | 252 | 0.020 |
Why?
|
| Bell Palsy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 16 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 375 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 619 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2011 | 45 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 745 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 97 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 28 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 393 | 0.020 |
Why?
|
| Medicaid | 1 | 2009 | 206 | 0.020 |
Why?
|
| African Americans | 1 | 2011 | 485 | 0.020 |
Why?
|
| Iowa | 1 | 2005 | 38 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 20 | 0.020 |
Why?
|
| Knowledge Bases | 1 | 2005 | 3 | 0.020 |
Why?
|
| Systems Integration | 1 | 2005 | 4 | 0.020 |
Why?
|
| Apgar Score | 1 | 2005 | 5 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 32 | 0.020 |
Why?
|
| Body Height | 1 | 2005 | 59 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 350 | 0.010 |
Why?
|